YOU ARE NOW LEAVING IDERACLINICALTRIALS.COM
The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.
CANCEL CONTINUEWe are conducting clinical trials of new potential medicines based on our Toll-like receptor and RNA-targeting technologies for people with cancer and rare diseases.
In the Illuminate clinical trials, researchers are evaluating an investigational drug called tilsotolimod (IMO-2125) to help treat patients with metastatic melanoma and other types of cancer.